More specifically, people with diabetes mellitus encounter death due to complications such as retinopathy, nephropathy, cardiomyopathy, etc.11 Likewise, in cancer, early-stage diagnosis is the need of the hour.12 Gootenberg et al. showed that CRISPR could identify the EGFR L858R mutation or exon 19 deletion in patients with non-small cell lung cancer (NSCLC).13 Similarly, CRISPR has the potential to detect gene mutations in cancer patients,14 which confirms that the cancer therapies and diagnostics will surely be transformed by CRISPR-Cas enzymes, resulting in clinical benefit. Here, EGFR is linked to non-small cell lung carcinoma.